In the News
Anti-competitive behaviour in market for hydrocortisone tablets
4th March 2017
On the surface this is a classic example of anti-competitive behaviour in a duopolistic market.
The CMA has alleged that Concordia and Actavis signed illegal agreements which enabled high prices for a life-saving drug to be prolonged. Naturally the announcement has brought a wave of criticism for the businesses involved because the cost of higher prices for drugs routinely used in the NHS are ultimately paid for by the taxpayer.
You can read more about the case here on the CMA website
- Economics
- Blog
- In the News
- Anti-Competitive Behaviour
- Price fixing
- Competition and Markets Authority (CMA)
- Cartel
- Duopoly
Geoff Riley
Geoff Riley FRSA has been teaching Economics for over thirty years. He has over twenty years experience as Head of Economics at leading schools. He writes extensively and is a contributor and presenter on CPD conferences in the UK and overseas.
You might also like
Competition and Markets Authority (CMA)
Study Notes
Ladbrokes and Coral merger approved
27th July 2016
Should the monopoly power of the tech titans be broken up?
10th September 2018
Horizontal and Vertical Collusion
Topic Videos
What is market power?
Topic Videos
Industry Profile: UK Supermarket Industry
Topic Videos